Roth Capital Partners launched coverage of Soliton (NASDAQ:SOLY) with a “buy” rating and $14 price target. The stock closed at $8.80 on March 26. Soliton is an aesthetic company that utilizes acoustic pulse technology...
Roth Capital Partners launched coverage of Daxor (NYSE American:DXR) with a “neutral” rating and $18 price target. The stock closed at $9.62 on Sept. 27. Daxor is an investment management company, with a medical device...
Roth Capital Partners downgraded NovaBay Pharmaceuticals (NYSE American:NBY) to “neutral” from “buy” and lowered its price target to $4 from $5, pending renewed prescription growth for the eyelid hygiene treatment...
Roth Capital Partners initiated coverage of Myomo (NYSE American:MYO) with a “buy” rating and $9 price target. The stock closed at $4.15 on March 8. Analyst Scott Henry writes that the MyoPro robotic arm brace offers...